How Novavax Has a 2-Pronged Approach to Vaccine Sales

When novel coronavirus vaccine developers resumed their clinical studies in the last week, not all drug manufacturing stocks rose. Shares of biotechnology firm Novavax (NASDAQ:NVAX) topped $120 in mid-October, but NVAX stock approached the end of the month around $80. Source: Ascannio/Shutterstock.com Why is NVAX stock falling and what will it take for investors to buy it from here? NVAX Stock Missing a Catalyst On Oct. 23, regulators approved AstraZeneca’s (NYSE:AZN) U.S. trial...